Ingredient or product comparison
GHK-Cu SubQ vs Topical: Delivery Method Comparison
Subcutaneous Injection 85–95% bioavailable within 2 hours 1–2.5mg per injection 18–24 hours sustained release Targets reticular dermis and subcutaneous junction. Stimulates fibroblasts at 1–4mm depth Maximum efficacy for deep dermal remodeling; requires steril
This source-based comparison does not add ratings or recommend a winner.
- Subcutaneous Injection
- 85–95% bioavailable within 2 hours
- 1–2.5mg per injection
- 18–24 hours sustained release
- Targets reticular dermis and subcutaneous junction. Stimulates fibroblasts at 1–4mm depth
- Maximum efficacy for deep dermal remodeling; requires sterile technique and causes minor discomfort
- Topical Serum (1% GHK-Cu)
- 3–7% dermal penetration
- 10–20mg applied topically (only 0.3–1.4mg absorbed)
- 4–6 hours before degradation
- Limited to papillary dermis (upper 0.3mm). Minimal effect on deeper collagen layers
- Convenient and non-invasive but requires 10× higher concentrations to approach subQ efficacy
- Microneedling + Topical
- 15–30% penetration with 0.5mm needles
- 10mg applied post-needling (1.5–3mg absorbed)
- 6–8 hours
- Reaches mid-dermis (0.5–1mm depth) depending on needle length
- Bridging method. Better than topical alone but still limited vs direct subQ placement
- Before using this table: subcutaneous injection is the most direct method to deliver GHK-Cu to fibroblast-rich dermal layers where collagen I and III synthesis occurs. Topical application is limited by the stratum corneum barrier. Even advanced delivery systems (liposomes, nanosomes) achieve only 7–12% penetration. Microneedling improves topical absorption but creates temporary inflammation that may interfere with peptide signaling during the critical 48-hour post-injection window.